🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› London
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in London

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2852 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 17 Sep 2026, 08:23 UTC
2852
Studies in scope
industry-sponsored, all four open statuses
1378
Recruiting now
open to new participants
540
Lead sponsors
across recruiting studies
Top sites
London 2010 Manchester 675 Birmingham 472 Glasgow 439 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Merck Sharp & Dohme LLC99 Hoffmann-La Roche80 Janssen Research & Development, LLC73 Novartis Pharmaceuticals72
Site city
London2010 Manchester675 Birmingham472 Glasgow439 Cambridge416
All 426 cities
Target enrolment
to
2010 of 2852 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Birmingham, London, Glasgow, Cardiff, Manchester
2027-11-23
Not yet open
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
NCT07441408Pulmonary Fibrosis
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
NCT07815574Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Scancell Ltd
Phase 3
550
London
2026-12-01
Not yet open
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
NCT07728188Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 3
520
Plymouth, Edinburgh, London, Portsmouth, Airdrie, Nottingham
2026-11-30
Not yet open
First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT07032038Sensorineural Hearing Loss, Presbyacusis, Auditory Neuropathy
Rinri Therapeutics
Phase 1/2
20
Birmingham, Cambridge, London
2026-11
Not yet open
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of ABI-6250 in Participants With Chronic Hepatitis D Virus Infection
NCT07762027Chronic Hepatitis D Infection
Assembly Biosciences
Phase 2
80
London, Manchester
2026-10
Not yet open
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer
NCT07808151Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer
Solstice Oncology, Inc.
Phase 2
100
Aberdeen, Cardiff, Glasgow, Leeds, London
2026-09-30
Not yet open
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
NCT07768189Oropharyngeal Carcinoma (OPC)
Corbus Pharmaceuticals Inc.
Phase 3
260
London
2026-09-20
Not yet open
FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
NCT07540988Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Leeds, Leicester, London, Manchester, Oxford
2026-09-14
Recruiting
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
NCT07648264Secondary Immune Deficiency
CSL Behring
Phase 3
63
London, Leicester
2026-09-11
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
Vividion Therapeutics, Inc.
Phase 2
140
London, Coventry
2026-09-11
Recruiting
Phase 2b Study of a Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Protein Vaccine Candidate in Adults 60 Years of Age and Older
NCT07810010Respiratory Syncytial Virus, Human Metapneumovirus, Healthy Volunteers
Sanofi
Phase 2
8,000
Cardiff, Bournemouth, Dorchester, London, Portsmouth, Blackpool, Witney, West Kirby
2026-09-09
Not yet open
A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)
NCT07640984Mucopolysaccharidosis IIIB
JCR Pharmaceuticals Co., Ltd.
Phase 1/2
12
London
2026-09-09
Recruiting
A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
NCT07623200Essential Thrombocythemia
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
NCT07623161Myelofibrosis, Anemia
Takeda
Phase 3
324
Lincoln, Leicester, London, Sunderland, Birmingham
2026-09-02
Not yet open
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
AstraZeneca
Phase 3
1,072
London, Newcastle upon Tyne, Sheffield
2026-09-01
Not yet open
An Investigation Into Dielectric Testing for the Evaluation and Characterisation of Breast Tissue Using a Novel Time-Domain Bioimpedance Tool
NCT07782814Breast Cancer, Breast - Female
Zedsen Limited
Observational
220
London
2026-09
Recruiting
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT07665515Ovarian Cancer, HGSOC, HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Epitopea Ltd
Phase 1
50
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
2026-09
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
Eli Lilly and Company
Phase 3
170
Hull, Liverpool, London
2026-09
Recruiting
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07680764Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2
160
London, Birmingham, Guildford
2026-08-31
Not yet open
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
NCT07781345Alzheimers Disease
Eisai Limited
Observational
400
Edinburgh, London, Motherwell
2026-08-31
Not yet open
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)
NCT07603557Chronic Immune Thrombocytopenia, Autoimmune Hemolytic Anemia
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
52
London, Sheffield
2026-08-31
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT07743463Obesity, Overweight, Chronic Weight Management
Ascletis Pharma (China) Co., Limited
Phase 3
3,003
Bellshill, Cardiff, Edgbaston, London, Manchester, Stoke-on-Trent, Warrington
2026-08-31
Not yet open
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
NCT07335562Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
92
London, Leeds, Sheffield
2026-08-29
Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT07743450Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
Ascletis Pharma (China) Co., Limited
Phase 3
1,560
Cardiff, Edgbaston, Glasgow, London, Manchester, Stoke-on-Trent, Warrington
2026-08-28
Rows per page Showing 1–25 of 2010
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 September 2026. https://priyalifescience.com/clinical-trials-uk/city/london

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.